Bio-Techne (TECH) Faces Merger Lawsuit, Voluntarily Supplements Proxy Disclosures Ahead of Key Shareholder Vote

gurufocus.com · 2026-09-15

Bio-Techne Corporation (TECH) disclosed in a Form 8-K filing that it is facing litigation and shareholder demands related to its pending merger with Merck KGaA

TickrTrends take: Bio-Techne's supplemental proxy disclosures and the pending merger lawsuit introduce legal and governance uncertainties that could affect shareholder value realization and the timeline for the proposed transaction. TickrTrends currently rates TECH as undervalued, so investors monitoring this situation should track whether the lawsuit resolution and disclosure updates influence shareholder voting outcomes or deal terms. The legal proceeding represents a material risk factor that could impact the company's near-term stock performance relative to its current valuation assessment.

Read the full story at gurufocus.com →